Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ligand Enters into OmniAb\u00ae Platform License Agreement with Pandion Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pandion Announces First Subject Dosed in a Phase 1 Clinical Trial of PT101","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Access Biotechnology","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pandion Raises $80 Million Series B to Advance Autoimmune Therapies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pandion Therapeutics Announces Issuance of U.S. Patent for Bifunctional Molecules Derived from TALON\u2122 Platform","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pandion Therapeutics Raises $75 million IPO","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pandion Therapeutics Highlights Potential of Modular Biologics Pipeline for the Treatment of Autoimmune Diseases at FOCIS 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$1,850.0 million","upfrontCash":"$1,850.0 million","newsHeadline":"Merck to Acquire Pandion Therapeutics","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pandion Therapeutics Presents Preclinical Data on Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"KBI Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Selexis Enters Service Agreement with Pandion Therapeutics to Advance Pandion Antibody","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$1,850.0 million","upfrontCash":"$1,850.0 million","newsHeadline":"Merck Completes Acquisition of Pandion Therapeutics","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Pandion Therapeutics

    Menu

    Pandion Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Pandion Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Merck Completes Acquisition of Pandion Therapeutics

              Details:

              Pandion's lead candidate, PT101, is an engineered IL-2 mutein fused to a protein backbone designed to selectively activate and expand regulatory T cells (Tregs) for the potential treatment of ulcerative colitis and other autoimmune diseases.

              Lead Product(s): PT101

              Therapeutic Area: Gastroenterology Product Name: PT101

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Merck & Co

              Deal Size: $1,850.0 million Upfront Cash: $1,850.0 million

              Deal Type: Acquisition April 01, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Pandion Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Selexis Enters Service Agreement with Pandion Therapeutics to Advance Pandion Antibody

              Details:

              Under the terms of the agreement, Pandion will utilize Selexis’ proprietary SUREtechnology Platform™ to rapidly develop the research cell banks (RCBs) necessary to advance PT627 to human trials.

              Lead Product(s): PT627

              Therapeutic Area: Immunology Product Name: PT627

              Highest Development Status: Preclinical Product Type: Large molecule

              Recipient: KBI Biopharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement March 16, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Pandion Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Merck to Acquire Pandion Therapeutics

              Details:

              Pandion's lead candidate, PT101, is an engineered IL-2 mutein fused to a protein backbone designed to selectively activate and expand regulatory T cells (Tregs) for the potential treatment of ulcerative colitis and other autoimmune diseases.

              Lead Product(s): PT101

              Therapeutic Area: Gastroenterology Product Name: PT101

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Merck & Co

              Deal Size: $1,850.0 million Upfront Cash: $1,850.0 million

              Deal Type: Acquisition February 25, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Pandion Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Pandion Therapeutics Presents Preclinical Data on Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease

              Details:

              The research, done in collaboration with St Vincent’s Institute of Medical Research in Australia and funded by JDRF and the JDRF T1D Fund, showed that PT001 treatment delayed the onset of hyperglycemia in a mouse model of Type 1 diabetes.

              Lead Product(s): Glycopyrronium Bromide

              Therapeutic Area: Immunology Product Name: PT001

              Highest Development Status: Preclinical Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 22, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Pandion Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Pandion Therapeutics Highlights Potential of Modular Biologics Pipeline for the Treatment of Autoimmune Diseases at FOCIS 2020

              Details:

              Pandion utilizes its TALON (Therapeutic Autoimmune reguLatOry proteiN) drug design and discovery platform to create antibody-based candidates that target known control nodes in the immune system.

              Lead Product(s): Glycopyrronium Bromide

              Therapeutic Area: Immunology Product Name: PT001

              Highest Development Status: Preclinical Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 28, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Pandion Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Pandion Therapeutics Raises $75 million IPO

              Details:

              Funds will be used in company's lead asset, PT101, a combination of an interleukin-2 mutein effector module with a protein backbone, designed to selectively expand regulatory T cells systemically without activating proinflammatory cells.

              Lead Product(s): PT101

              Therapeutic Area: Gastroenterology Product Name: PT101

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $75.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering June 29, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Pandion Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Pandion Therapeutics Announces Issuance of U.S. Patent for Bifunctional Molecules Derived from TALON™ Platform

              Details:

              Patent protects foundational intellectual property and pioneering work on Pandion’s therapeutic autoimmune regulatory protein (TALON) drug design platform.

              Lead Product(s): PT101

              Therapeutic Area: Gastroenterology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 09, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Pandion Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Pandion Raises $80 Million Series B to Advance Autoimmune Therapies

              Details:

              Proceeds to support advancement of pipeline of modular proteins and bifunctional antibodies for autoimmune diseases, including lead clinical-stage IL?2 mutein program.

              Lead Product(s): PT101

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Access Biotechnology

              Deal Size: $80.0 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing April 01, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Pandion Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Pandion Announces First Subject Dosed in a Phase 1 Clinical Trial of PT101

              Details:

              Trial to evaluate safety and tolerability of PT101, as well as expansion of regulatory T cells.

              Lead Product(s): PT101

              Therapeutic Area: Gastroenterology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 24, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Pandion Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ligand Enters into OmniAb® Platform License Agreement with Pandion Therapeutics

              Details:

              Under the agreement, Pandion will be able to use Ligand’s full OmniAb antibody discovery platform which includes OmniRat®, OmniFlic®, OmniMouse®, OmniChicken® and OmniClic™.

              Lead Product(s): Antibodies

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Recipient: Ligand Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 13, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY